Middle Meningeal Artery Embolization for Management of Chronic Subdural Hematoma
Issued Date
2024-04-01
Resource Type
eISSN
15271323
Scopus ID
2-s2.0-85187195654
Pubmed ID
38451847
Journal Title
Radiographics : a review publication of the Radiological Society of North America, Inc
Volume
44
Issue
4
Rights Holder(s)
SCOPUS
Bibliographic Citation
Radiographics : a review publication of the Radiological Society of North America, Inc Vol.44 No.4 (2024) , e230158
Suggested Citation
Schmolling Á.H., Pérez-García C., Trejo C., López-Frías A., Jaroenngarmsamer T., Rosati S., Arrazola J., Moreu M. Middle Meningeal Artery Embolization for Management of Chronic Subdural Hematoma. Radiographics : a review publication of the Radiological Society of North America, Inc Vol.44 No.4 (2024) , e230158. doi:10.1148/rg.230158 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97633
Title
Middle Meningeal Artery Embolization for Management of Chronic Subdural Hematoma
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Chronic subdural hematoma (CSDH) is a prevalent medical condition with potentially severe consequences if left untreated. While surgical removal has traditionally been the standard approach for treatment, middle meningeal artery (MMA) embolization has emerged as a promising minimally invasive alternative to reduce recurrences. This comprehensive review provides the general radiology community with an overview of MMA embolization as a therapeutic option for managing CSDH. The authors base their insights on existing evidence and their institutional experience. This overview encompasses the pathophysiology of CSDH as well as the potential advantages and limitations, safety profile, and potential complications of MMA embolization as compared with surgical treatment. The imaging findings seen before and after MMA, as well as insights into the procedural techniques used at the authors' institution, are described. On the basis of reports in the current literature, MMA embolization appears to be a safe and effective therapeutic option for managing CSDH, especially in patients who are unsuitable for surgery or at risk for recurrence. Nonetheless, further research is needed to validate these findings. Results from ongoing clinical trials hold promise for future validation and the establishment of scientific evidence. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material. See the invited commentary by Chatterjee in this issue.